Ardelyx and Knight Collaborate to Bring Tenapanor to Patients in Canada

March 19, 2018

Responsive image

FREMONT, Calif., March 19, 2018 /PRNewswire/ — Ardelyx, Inc. (NASDAQ: ARDX) today announced a license agreement with Knight Therapeutics, Inc. (TSX: GUD) (Knight) that provides Knight with exclusive rights to commercialize tenapanor in Canada. Tenapanor is Ardelyx’s oral, first-in-class…

Category: Precious Metals